Treace Q4 revenue $33.4M (+39% YoY); FY22 guidance $125-130M (32-38% growth)

TREACE MEDICAL CONCEPTS, INC.

Full-year 2021 revenue $94.4M (+65% YoY); net loss ($20.7M) or ($0.43)/share vs. ($4.3M) in 2020.
Q4 gross margin 81.1% (+220 bps YoY); operating expenses $32.7M from $15.4M in Q4 2020.
Cash $105.8M at Dec 31; FY22 revenue guided $125-130M.
ALIGN3D clinical data: 0.9% recurrence at 12 months, 0.0% at 24 months post-Lapiplasty.
Expanded patent portfolio: 32 granted US patents, over 30 pending applications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.